Medical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, Burn and Combined Injury, Army Medical University, Chongqing 400037, China.
Peking University People's Hospital & Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China.
Chin Med J (Engl). 2022 Jun 20;135(12):1394-1403. doi: 10.1097/CM9.0000000000002235.
Hematopoietic stem cell transplantation (HSCT) is a highly effective and unique medical procedure for the treatment of most hematological malignancies. The first allogeneic transplantation was performed by E. Donnall Thomas in 1957. Since then, the field has evolved and expanded worldwide. The first successful allogenic HSCT (allo-HSCT) in China was conducted in 1981. Although the development of allo-HSCT in China lagged, China has since made considerable contributions to the process of HSCT worldwide, with more than 10,000 HSCTs performed annually. In particular, haploid HSCT (haplo-HSCT) technology represented in the Beijing Protocol has demonstrated similar efficacy to human leukocyte antigen-matched HSCT and has gradually become the pre-dominant choice for allo-HSCT in China. Currently, the number of haplo-HSCT procedures exceeds 5000 per year, and the Beijing Protocol has been greatly improved by implementing updated individualized strategies for controlling complications, relapse, and infection management. In addition, innovative haplo-HSCT technologies developed by different medical transplantation centers, such as Soochow, Zhejiang, Fujian, Chongqing, and Anhui, have emerged, providing inspiration for the refinement of global practice. This review will focus on the current activity in this field and highlight important trends that are vital in China's allo-HSCT process, examining the current viewpoint and future directions.
造血干细胞移植（HSCT）是治疗大多数血液恶性肿瘤的一种非常有效且独特的医疗程序。首例异基因移植由 E. Donnall Thomas 于 1957 年完成。此后，该领域在全球范围内不断发展和扩展。中国首例成功的异基因 HSCT（allo-HSCT）于 1981 年进行。尽管 allo-HSCT 在我国的发展滞后，但此后我国为全球 HSCT 进程做出了巨大贡献，每年进行的 HSCT 超过 10000 例。特别是北京方案中提出的单倍体 HSCT（haplo-HSCT）技术与人类白细胞抗原匹配 HSCT 具有相似的疗效，并逐渐成为我国 allo-HSCT 的首选。目前，haplo-HSCT 手术每年超过 5000 例，通过实施控制并发症、复发和感染管理的个体化策略，北京方案得到了极大的改进。此外，苏州、浙江、福建、重庆和安徽等不同医疗移植中心开发的创新 haplo-HSCT 技术也相继出现，为全球实践的精细化提供了启示。本综述将重点关注该领域的当前活动，并强调在中国 allo-HSCT 进程中至关重要的重要趋势，探讨当前的观点和未来的方向。
